| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090093417 angiotensin II type 1 (AT1) receptor antagonist activity and neprilysin inhibition activity; aryl compounds with both tert-amide and another tert or sec-amide group |
| 04/09/2009 | US20090093416 Caspase inhibitors and uses thereof |
| 04/09/2009 | US20090093415 Therapeutic agent for irritable bowel syndrome |
| 04/09/2009 | US20090093414 methotrexate- alpha -PhePhe-NHC10H20O3NHCO O-hyaluronic acid; therapeutical agent; oseoarthritis (degenerative diseases ) |
| 04/09/2009 | US20090093413 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093412 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093411 Long-acting hormone and growth factor compositions and uses thereof |
| 04/09/2009 | US20090093410 Methods for Local Treatment with Factor VII |
| 04/09/2009 | US20090093409 Neuroprotective synergy of erythropoietin and insulin-like growth factors |
| 04/09/2009 | US20090093408 Protection of exendin-4 peptides through conjugation |
| 04/09/2009 | US20090093407 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 04/09/2009 | US20090093406 Vegetable Protein Concentrate Having a Reduced Insoluble Dietary Fiber Content and Increase Amount of Soluble Dietary Fiber Content |
| 04/09/2009 | US20090093405 Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity |
| 04/09/2009 | US20090093404 Accelerated angiogenesis-inducing protein, compositions inducing accelerated angiogenesis and uses thereof |
| 04/09/2009 | US20090093403 Systems, methods and compositions for optical stimulation of target cells |
| 04/09/2009 | US20090093402 Albumin Fusion Proteins |
| 04/09/2009 | US20090093401 Administering Cycstatin C homologues to inhibit transforming growth factor-beta stimulation of epithelial-mesenchymal transitions (EMT); antineoplastic agents |
| 04/09/2009 | US20090093400 Truncated keratinocyte growth factor (KGF) having increased biological activity |
| 04/09/2009 | US20090093399 Glycopegylation methods and proteins/peptides produced by the methods |
| 04/09/2009 | US20090093398 Use of Fibroblast Growth Factor Fragments |
| 04/09/2009 | US20090093397 Phaseolus vulgaris extracts, their use, and formulations containing them |
| 04/09/2009 | US20090093396 Diagnostics and therapeutics for restenosis |
| 04/09/2009 | US20090093395 Method for determining predisposition to pulmonary infection |
| 04/09/2009 | US20090093393 Methods For Selective Targeting |
| 04/09/2009 | US20090093057 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 04/09/2009 | US20090093026 TRANSDUCIBLE DELIVERY OF siRNA BY dsRNA BINDING DOMAIN FUSIONS TO PTD/CPPS |
| 04/09/2009 | US20090093000 Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease |
| 04/09/2009 | US20090092995 Method for Identifying Within a Mammal a DNA encoding a Physiologically Active Polypeptide |
| 04/09/2009 | US20090092992 Novel human dickkopf-related protein and nucleic molecules and uses therefor |
| 04/09/2009 | US20090092963 Method for combined parallel agent delivery and electroporation for cell structures an use thereof |
| 04/09/2009 | US20090092678 Universally applicable blood plasma |
| 04/09/2009 | US20090092665 OPHTHALMIC COMPOSITIONS COMPRISING CALCINEURIN INHIBITORS OR mTOR INHIBITORS |
| 04/09/2009 | US20090092664 Polymer-metal chelator conjugates and uses thereof |
| 04/09/2009 | US20090092663 Tumor-targeted drug delivery systems and uses thereof |
| 04/09/2009 | US20090092654 Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System |
| 04/09/2009 | US20090092650 Sustained Delivery Formulations of Octreotide Compounds |
| 04/09/2009 | US20090092625 administering hematopoietic cells to increase blood platelet; for patient receiving cancer chemotherapy or radiation therapy, or immunosuppressants; treating blood disorders anemia, myeloma, non-Hodgkin's lymphoma, Hodgkins lymphoma and leukaemia |
| 04/09/2009 | US20090092622 Molecules, compositions, methods and kits for applications associated with flaviviruses |
| 04/09/2009 | US20090092617 Erbb Receptor-Derived Peptide Fragments |
| 04/09/2009 | US20090092615 biodrugs select from an oligopeptide, or polypeptide; anticarcinogenic agent for treating lung cancer cell, adenocarcinoma cell; combination therapy using standard anti-cancer protocols in conjunction with Notch proteins |
| 04/09/2009 | US20090092613 Novel TNF receptor death domain ligand proteins and inhibitors of ligand binding |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092607 Fc-erythropoietin fusion protein with improved pharmacokinetics |
| 04/09/2009 | US20090092606 Antibacterial treatments |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092604 Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity |
| 04/09/2009 | US20090092600 Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| 04/09/2009 | US20090092594 Mammalian genes involved in viral infection and tumor suppression |
| 04/09/2009 | US20090092592 Methionyl tRNA Synthetase Polynucleotides |
| 04/09/2009 | US20090092591 Use of a Mixture of Superoxide Dismutase and Catalase for Treating Inflammatory Skin Lesions |
| 04/09/2009 | US20090092590 Method for improving stool characteristics in infants |
| 04/09/2009 | US20090092587 Laminins, derivatives, and compositions including same and methods for their therapeutic use |
| 04/09/2009 | US20090092586 Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
| 04/09/2009 | US20090092582 Compositions and methods for modifying properties of biologically active polypeptides |
| 04/09/2009 | US20090092581 Interferons of rhesus and cynomolgus origin and uses thereof |
| 04/09/2009 | US20090092580 Dialkyl ether delivery agents |
| 04/09/2009 | US20090092579 Novel method for down-regulation of amyloid |
| 04/09/2009 | US20090092578 Methods of selecting and producing modified toxins, conjugates containing modified toxins, and uses thereof |
| 04/09/2009 | US20090092557 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
| 04/09/2009 | US20090092555 Octameric Protein For Use In Bionanotechnology Applications |
| 04/09/2009 | US20090092546 Carrier molecules |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092543 Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells |
| 04/09/2009 | DE4021517B4 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Formulations with delayed release of water-soluble peptides |
| 04/09/2009 | DE19543553B4 VP-Antigene des JC-Virus VP-antigens of the JC virus |
| 04/09/2009 | CA2739523A1 Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors |
| 04/09/2009 | CA2710406A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2701686A1 Methods of treating cancer using notch pathway inhibitors |
| 04/09/2009 | CA2701612A1 Neuromedin u derivative |
| 04/09/2009 | CA2701521A1 Use of the sequence encoding of the carboxyl-terminal domain of the heavy chain of the tetanus toxin as a drug |
| 04/09/2009 | CA2701494A1 Method of regulating the th17 pathway and its associated metabolic impact |
| 04/09/2009 | CA2701470A1 Sustained delivery of compstatin analogs from gels |
| 04/09/2009 | CA2701377A1 Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof |
| 04/09/2009 | CA2701215A1 Articular cartilage gene therapy with recombinant vector encoding bmp-7 |
| 04/09/2009 | CA2701172A1 Methods of treating neurological autoimmune disorders with cyclophosphamide |
| 04/09/2009 | CA2701023A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| 04/09/2009 | CA2699597A1 Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1 |
| 04/09/2009 | CA2699264A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2699260A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699255A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699114A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699113A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699109A1 Use of urocortin and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699107A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | CA2699105A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699104A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699078A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699074A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699067A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | CA2698690A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2698688A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2698687A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2696417A1 Therapeutic antibody purification method and method of use |
| 04/08/2009 | EP2045324A1 Method for production of n36-binding peptide |
| 04/08/2009 | EP2045269A1 Novel chimeric analgesic peptides |
| 04/08/2009 | EP2045267A2 Humanized antibodies that recognize beta amyloid peptide |
| 04/08/2009 | EP2045261A1 Chlamydia pneumoniae antigenic polypeptides |
| 04/08/2009 | EP2044955A2 Methods for detecting and inhibiting angiogenesis |
| 04/08/2009 | EP2044952A2 Use of the pedf factor to induce cell regeneration |